Publication details

Circulating Levels of B-cell Activating Factor in Paediatric Patients with Malignancy With or without Cancer-Related Cachexia

Authors

BIENERTOVÁ VAŠKŮ Julie LUNGOVÁ Alena BIENERT Petr ZLÁMAL Filip TOMANDL Josef TOMANDLOVÁ Marie ŠPLÍCHAL Zbyněk ŠTĚRBA Jaroslav

Year of publication 2012
Type Article in Periodical
Magazine / Source Klinická onkologie
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords B cell-activating factor; cachexia; cancer; paediatrics
Attached files
Description Cancer-related cachexia is a multifactorial syndrome characterised by progressive loss of body weight and it affects a large proportion of patients with advanced cancer. Cachexia is associated with reduced treatment tolerance, response to therapy, quality of life and duration of survival, whereas some of its mechanisms are shared across the whole continuum of diseases in the population, either cancer-related or non-cancer related e.g. systemic inflammation, increased lipolysis, insulin resistance and reduced physical performance. However, so far there has been only little effort to utilise the integrative physiology of adipose tissue to achieve therapeutic gain. B cell-activating factor (BAFF) is a novel member of the TNF ligand superfamily, is mainly produced by myeloid cells and has recently been shown to participate in B-cell survival and B- and T-cell maturation, but also in adipogenesis. Therefore, it represents an elegant candidate molecule linking the immune system and adipose tissue metabolism, both being involved deeply in the pathogenesis of cachexia. Moreover, it has been described very recently that BAFF directly influences secretion of IL-6 and IL-10.

You are running an old browser version. We recommend updating your browser to its latest version.

More info